Daiichi Sankyo (4568) Report Interpretation

Overview

Goldman Sachs reviews Daiichi Sankyo’s 1Q FY3/27 results, which beat its expectations on stronger core-product sales. While revised operating-profit guidance remains below prior Goldman Sachs and consensus estimates, the firm considers the underlying variance limited after accounting for inventory losses and higher strategic investment, and maintains Buy.

Core views

Daiichi Sankyo reported 1Q FY3/27 sales of ¥574.7bn and operating profit of ¥85.1bn, above Goldman Sachs estimates of ¥517.7bn and ¥79.6bn, respectively. The outperformance was driven by core products, notably the cancer drug Enhertu and anticoagulant Lixiana. Profit exceeded expectations by less than sales because costs were also higher than expected, reflecting inventory-related valuation losses and greater strategic investment. The company raised FY3/27 sales guidance to ¥2,340.0bn from ¥2,280.0bn and operating-profit guidance to ¥320.0bn from ¥315.0bn; core operating-profit guidance remained ¥360.0bn. The changes reflected first-quarter results, a USD/JPY assumption change from ¥150 to ¥155 from 2Q onward, stronger core-product performance, and revised cost assumptions including the first-quarter valuation loss, higher strategic investment and reversal of guarantee provisions. The new sales target is close to Goldman Sachs’ prior ¥2,360.9bn estimate and above I/B/E/S consensus of ¥2,318.5bn, while operating-profit guidance is 6-11% below Goldman Sachs’ prior ¥339.0bn estimate and consensus of ¥358.7bn. Goldman Sachs nevertheless judges the underlying deviation from its prior expectations not significant. Goldman Sachs revised sales and cost assumptions following the results and guidance, raising assumptions for core-product sales but also increasing SG&A assumptions. It consequently reduced FY3/27-FY3/31 operating-profit estimates by 1-5% and trimmed its 12-month target price to ¥4,250 from ¥4,300. The target is derived from a 12-year DCF using a 6% WACC and 0% terminal growth rate, both unchanged. The firm maintains Buy, citing longer-term potential from expansion of the antibody-drug conjugate franchise. It highlights potential expectation-building catalysts from overall-survival data in DESTINY-Breast09 for Enhertu, Dato-DXd development, Merck-partnered drug progress, and Datroway first-line non-small-cell-lung-cancer trial results: AVANZAR in 2H 2026 and TROPION-Lung07 and TROPION-Lung08 in 1H 2027.

Analysis framework

Goldman Sachs compares reported first-quarter sales and operating profit with its own estimates and consensus, separates core-product strength from cost pressures, and evaluates revised full-year guidance against prior forecasts. It then updates sales and SG&A assumptions, revises multi-year profit estimates, and values the company using a 12-year DCF framework.

Methodology notes

• Valuation methodsDCF (Discounted Cash Flow)

  12-year DCF model

  Goldman Sachs estimates the present value of long-term cash flows using a 6% WACC and a 0% terminal growth rate to derive its ¥4,250 target price.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Daiichi Sankyo (4568.T)

  Primary covered company; stronger core-product sales and longer-term ADC expansion underpin Goldman Sachs’ Buy rating.

  Strengths

  Enhertu and Lixiana outperformed in 1Q; the ADC franchise has multiple upcoming clinical catalysts.

  Weaknesses

  Higher costs, including inventory valuation losses and strategic investment, limited the operating-profit beat.

  Comparison

  FY3/27 sales guidance is near Goldman Sachs’ prior estimate, while operating-profit guidance is below both Goldman Sachs and I/B/E/S expectations.

  Risks

  Weaker key-drug sales, development delays or suspensions, product-evaluation changes, negative ADC news flow, and macro-related drug-price or healthcare-system changes.

Key data

• 1Q FY3/27 sales¥574.7bn11% above Goldman Sachs estimate of ¥517.7bn and 25% above consensus.
• 1Q FY3/27 operating profit¥85.1bn7% above Goldman Sachs estimate of ¥79.6bn and 27% above consensus.
• FY3/27 sales guidance¥2,340.0bnRaised from ¥2,280.0bn; near Goldman Sachs’ prior ¥2,360.9bn estimate.
• FY3/27 operating-profit guidance¥320.0bnRaised from ¥315.0bn but remains below Goldman Sachs’ prior ¥339.0bn estimate and ¥358.7bn consensus.
• Operating-profit estimate revision-1% to -5%Goldman Sachs lowered FY3/27-FY3/31 estimates after incorporating higher SG&A assumptions.
• 12-month target price¥4,250Lowered from ¥4,300; based on a 12-year DCF with 6% WACC and 0% terminal growth.

Impact & implications

The report argues that stronger sales of Enhertu and Lixiana support the longer-term ADC growth thesis. Although higher costs temper near-term profit estimates, Goldman Sachs considers revised guidance broadly consistent with its underlying expectations and maintains Buy.

Risks

• Sales of key drugs could be weaker than expected.
• Drug-development programs could be suspended or delayed.
• Changes in product evaluation or negative news concerning the ADC franchise could weaken the thesis.
• Macro conditions, including changes in global drug prices and healthcare systems, particularly in the US, could affect results.

What to watch

• AVANZAR first-line non-small-cell-lung-cancer trial results for Datroway in 2H 2026.
• TROPION-Lung07 and TROPION-Lung08 results, scheduled for 1H 2027.
• Overall-survival data from DESTINY-Breast09 for Enhertu in first-line HER2-positive breast cancer.
• Progress of Dato-DXd and drugs being developed with Merck.